Biomarker-directed therapy of squamous carcinomas of the head and neck: Targeting PI3K/PTEN/mTOR pathway

Journal of Clinical Oncology

Volumn 31, Issue 9, 2013, Pages

  Holsinger, Floyd Christopher ^a   Piha Paul, Sarina Anne ^a   Janku, Filip ^a   Hong, David S ^a   Atkins, Johnique T ^a   Tsimberidou, Apostolia M ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMSIROLIMUS;

ADOLESCENT; ADULT; AGED; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EXON; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED;

EID: 84875978234     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.2716     Document Type: Note

References (21)

1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
2. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000 (Pubitemid 30365531)
3. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
4. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998 (Pubitemid 28277960)
5. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003 (Pubitemid 37464533)
6. Forastiere AA, Maor M, Weber RS, et al: Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx - Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 24:284s, 2006 (suppl; abstr 5517)
7. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007 (Pubitemid 350005152)
8. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
9. Shin DM, Khuri FR: Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2011.10.1002/hed.21910 [epub ahead of print on November 2, 2011]
10. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009
11. Molinolo AA, Hewitt SM, Amornphimoltham P, et al: Dissecting the Akt/mammalian target of rapamycin signaling network: Emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964-4973, 2007 (Pubitemid 47502060)
12. Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10:558-565, 2011
13. Janku F, Wheler JJ, Westin SN, et al: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30:777-782, 2012
14. Piha-Paul SA, Cohen PR, Kurzrock R: Salivary duct carcinoma: Targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29:e727-e730, 2011
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Langer CJ: Targeted therapy in head and neck cancer: State of the art 2007 and review of clinical applications. Cancer 112:2635-2645, 2008 (Pubitemid 351969206)
17. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
18. Wu X, Senechal K, Neshat MS, et al: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95:15587-15591, 1998 (Pubitemid 29018743)
19. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554, 2006 (Pubitemid 43927103)
20. Magnuson B, Ekim B, Fingar DC: Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441:1-21, 2012
21. Hsieh AC, Costa M, Zollo O, et al: Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17:249-261, 2010